engineering
Investment in digital and AI-enabled capabilities
Not sized
AI adoption is named beside workforce enablement and Carelon scaling and nothing separates its part (the methodology rule for AI named beside another cause); the amounts are per share and cover all targeted investments, so they are a ceiling, not a size. The rise in adjusted operating expense is kept in the metrics as the ceiling line’s movement and is not read as a shape, since the filings credit it to several causes and never to AI.
described, no sizedisclosure: described· motive: exploratory· before LLMs: expanded
The CFO says the 2026 outlook already held approximately of EPS of targeted investment spending that supports AI adoption, workforce enablement and Carelon scaling, and that approximately more will go to one-time investments in the second half. Adjusted operating expense was against , and ran above its prior-year share of operating revenue; the adjusted ratio rose from to . The 10-Q explains the rise by investments in the workforce and technology adoption, regulatory matters and premium taxes, never by AI. The Q1 amount, more than for digital and AI-enabled capabilities together, is not repeated.
Evidence: 8 quotes, 11 figures, 3 confounds, 3 from before coverage
What the company spends building and rolling out AI: the stated investment in digital and AI-enabled capabilities, the targeted investments the CFO says support AI adoption and workforce enablement beside Carelon scaling, and the one-time investments of the second half of 2026 in medical cost management, member engagement and provider connectivity. Management always names AI together with digital capabilities, technology adoption, workforce and Carelon, and never separates the AI part: the Q1 amount is a floor on digital and AI together, and the per-share investment amounts cover all targeted investments, so none of them sizes the AI part. Staff, vendor and model bills are not split, and part of the spend may be capitalized. The vendor bill is not registered apart because no vendor or model is named.
Why this motive
The CFO places AI adoption among the areas the targeted investments support (claim c8) and the CEO says the medical cost investments pay off next year (claim c3): investing for later, with no displaced line shown shrinking.
Before LLMs: expanded
At the anchor the FY2024 10-K already described investments in AI administrative tools and solutions (claim elv-anchor-c1) and an ongoing programme of digital technology and internal operating improvements (claim elv-anchor-c9), with no amount, against operating expense of for the year. The first call of 2024 carries no AI passage. The earlier size of AI spending is not traced, so the level has no baseline. The size is the whole of an activity that existed before.
“As part of our operations, we are making investments in certain AI administrative tools and solutions to enhance our operations and positively impact the experience of our members, and we continue to explore further innovation using AI.”
“In addition, connectivity amongst technologies is becoming increasingly important, with recent trends bringing greater consumer engagement in healthcare; therefore, the pace at which our customers will need enhanced technologies with sophisticated applications for mobile interfaces, including tools and products that leverage AI to improve the customer experience, will quicken.”
“We continue to enhance interactions with customers, providers, brokers, agents, employees and other stakeholders through digital technology and improvements to internal operations.”
Figures
- Targeted investment spending in the 2026 outlook, per diluted share (approximately; spans AI adoption, workforce enablement and Carelon scaling) · FY2026
- One-time accelerated investments planned for the second half of 2026, per diluted share (approximately) · 2026-07-01..2026-12-31
- Adjusted operating expense (release reconciliation) · 2026-CQ2
- Adjusted operating expense, prior-year quarter · 2025-CQ2
- Total operating revenue · 2026-CQ2
- Total operating revenue, prior-year quarter · 2025-CQ2
- Adjusted operating expense at the prior-year share of operating revenue · 2026-CQ2
- Adjusted operating expense above the prior-year share of operating revenue · 2026-CQ2
- Adjusted operating expense ratio · 2026-CQ2
- Adjusted operating expense ratio, prior-year quarter · 2025-CQ2
- Investment in digital and AI-enabled capabilities together, no period stated (more than; the AI part is not separated) · as-of 2026-04-22
What else could explain it
- line composition: The targeted investments support AI adoption beside workforce enablement and Carelon scaling (claim c8), and the 10-Q names workforce and technology adoption, regulatory matters and premium taxes (claim c13); no AI part is separated.
- one time item: The second-half investments funded by investment income are one-time (claims c9 and c10) and start after the quarter.
- other: The investment amounts are given per diluted share, not in dollars.
Quotes
“Medical cost management is really about investments in analytics and AI-enabled tools that, again, allow us to identify those pressures earlier, but more importantly, allow us to implement clinical oversight, payment integrity, changes in our network, those kind of interventions. Those take time to mature, but we need the data, we need the infrastructure in place this year, and we expect to see that next year.”
“On the investment spend here, the 2026 outlook from the first quarter already included approximately $0.75 of EPS tied to those targeted investment spending that we spoke about at the beginning of the year.”
“Those investments should be viewed as part of the ongoing run rate of the business, and that will support areas like AI adoption and workforce enablement, Carelon scaling, etc.”
“In addition, as we've spoken about this morning, we now expect to deploy approximately $0.80 of net below the line favorability from the second quarter into one-time accelerated investments in the second half.”
“We are looking at these as long-term, durable capabilities. Some are technology, but honestly, they're all driven based on improving the capabilities that we have inside of the business.”
“Operating expense increased primarily due to increases in targeted investments to support and strengthen our workforce and accelerate technology adoption, an increase in expenses to address regulatory matters and an increase in premium tax expenses and assessments.”
“The adjusted operating expense ratio was 11.0 percent, an increase of 100 basis points, driven primarily by targeted investments in our workforce and in capabilities that support our long-term operating model.”
“Beyond our EPS outlook, the principal operating elements of our full-year framework remain unchanged, though we now expect our adjusted operating expense ratio to be in the upper half of our full-year guidance range.”
By quarter
- Q1 2026described · described, no size · exploratory
- Q2 2026described · described, no size · exploratory